HRP20210236T1 - Formulacije zadržanog otpuštanja lorazepama - Google Patents

Formulacije zadržanog otpuštanja lorazepama Download PDF

Info

Publication number
HRP20210236T1
HRP20210236T1 HRP20210236TT HRP20210236T HRP20210236T1 HR P20210236 T1 HRP20210236 T1 HR P20210236T1 HR P20210236T T HRP20210236T T HR P20210236TT HR P20210236 T HRP20210236 T HR P20210236T HR P20210236 T1 HRP20210236 T1 HR P20210236T1
Authority
HR
Croatia
Prior art keywords
lorazepam
hours
release
granules
sustained release
Prior art date
Application number
HRP20210236TT
Other languages
English (en)
Croatian (hr)
Inventor
Douglas A. Saltel
Michael Vachon
Original Assignee
Edgemont Pharmaceuticals Llc Liquidating Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50064764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210236(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc Liquidating Trust filed Critical Edgemont Pharmaceuticals Llc Liquidating Trust
Publication of HRP20210236T1 publication Critical patent/HRP20210236T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20210236TT 2013-01-09 2014-01-09 Formulacije zadržanog otpuštanja lorazepama HRP20210236T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361750797P 2013-01-09 2013-01-09
US201361762833P 2013-02-08 2013-02-08
PCT/US2014/010854 WO2014110245A1 (en) 2013-01-09 2014-01-09 Sustained release formulations of lorazepam
EP14702977.1A EP2943185B1 (en) 2013-01-09 2014-01-09 Sustained release formulations of lorazepam

Publications (1)

Publication Number Publication Date
HRP20210236T1 true HRP20210236T1 (hr) 2021-03-19

Family

ID=50064764

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210236TT HRP20210236T1 (hr) 2013-01-09 2014-01-09 Formulacije zadržanog otpuštanja lorazepama

Country Status (30)

Country Link
US (3) US8999393B1 (enExample)
EP (1) EP2943185B1 (enExample)
JP (2) JP6039823B2 (enExample)
KR (1) KR102318274B1 (enExample)
CN (1) CN105209018B (enExample)
AU (1) AU2014205440B2 (enExample)
BR (1) BR112015016304A8 (enExample)
CA (1) CA2897302C (enExample)
CL (1) CL2015001920A1 (enExample)
CY (1) CY1123933T1 (enExample)
DK (1) DK2943185T3 (enExample)
ES (1) ES2856181T3 (enExample)
HR (1) HRP20210236T1 (enExample)
HU (1) HUE054005T2 (enExample)
IL (1) IL239777B (enExample)
LT (1) LT2943185T (enExample)
MX (1) MX367364B (enExample)
NZ (1) NZ710860A (enExample)
PE (1) PE20151432A1 (enExample)
PH (1) PH12015501534B1 (enExample)
PL (1) PL2943185T3 (enExample)
PT (1) PT2943185T (enExample)
RS (1) RS61857B1 (enExample)
RU (1) RU2678324C2 (enExample)
SG (1) SG11201505349RA (enExample)
SI (1) SI2943185T1 (enExample)
SM (1) SMT202100091T1 (enExample)
UA (1) UA117233C2 (enExample)
WO (1) WO2014110245A1 (enExample)
ZA (1) ZA201505082B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
CN111278434A (zh) * 2017-11-01 2020-06-12 埃奇蒙特医药信托有限公司 劳拉西泮的耐酒精口服药物组合物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (enExample) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
AU552261B2 (en) * 1980-01-21 1986-05-29 Wellcome Foundation Limited, The Use of propiophenone derivatives as adjuncts to benzo- diazepine tranquillisers
KR850700212A (ko) * 1984-03-21 1985-12-26 죠지 드모트 서방성 약제학적 캼셀제
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
AU682827B2 (en) 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
AU747549B2 (en) * 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
US6217904B1 (en) * 1999-04-06 2001-04-17 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
EP1250937B1 (en) 2001-04-09 2009-05-13 Rohm And Haas Company Controlled dissolution of active ingredients
EA005537B1 (ru) 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
WO2004000280A1 (en) 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
WO2006088894A2 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
US8277840B2 (en) 2005-07-22 2012-10-02 Emcure Pharmaceuticals Limited Sustained release formulation of alprazolam
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007079082A2 (en) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
KR101468053B1 (ko) * 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP2097067A2 (en) 2006-12-05 2009-09-09 University Of The Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
EP2285219B1 (en) * 2008-05-08 2018-07-18 Supernus Pharmaceuticals, Inc. Controlled release formulations of alprazolam
KR20110075011A (ko) 2008-11-10 2011-07-05 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
UA117233C2 (uk) 2018-07-10
PH12015501534A1 (en) 2015-10-05
PE20151432A1 (es) 2015-09-23
US20150174078A1 (en) 2015-06-25
HK1213770A1 (zh) 2016-07-15
CL2015001920A1 (es) 2016-01-29
RS61857B1 (sr) 2021-06-30
PH12015501534B1 (en) 2015-10-05
CY1123933T1 (el) 2022-05-27
LT2943185T (lt) 2021-03-10
IL239777B (en) 2019-03-31
WO2014110245A1 (en) 2014-07-17
HUE054005T2 (hu) 2021-08-30
RU2678324C2 (ru) 2019-01-28
CA2897302C (en) 2022-05-31
DK2943185T3 (da) 2021-02-15
NZ710860A (en) 2020-05-29
KR102318274B1 (ko) 2021-10-26
PL2943185T3 (pl) 2022-01-17
ZA201505082B (en) 2021-04-28
US20150110874A1 (en) 2015-04-23
PT2943185T (pt) 2021-02-18
ES2856181T3 (es) 2021-09-27
US20160228378A1 (en) 2016-08-11
SI2943185T1 (sl) 2021-04-30
BR112015016304A2 (pt) 2017-07-11
JP2016504390A (ja) 2016-02-12
SG11201505349RA (en) 2015-08-28
KR20150118119A (ko) 2015-10-21
SMT202100091T1 (it) 2021-03-15
AU2014205440A1 (en) 2015-08-27
MX2015008756A (es) 2016-03-31
CA2897302A1 (en) 2014-07-17
BR112015016304A8 (pt) 2018-01-23
EP2943185B1 (en) 2020-11-18
CN105209018B (zh) 2019-06-25
RU2015128915A (ru) 2017-02-10
JP6039823B2 (ja) 2016-12-07
IL239777A0 (en) 2015-08-31
AU2014205440B2 (en) 2018-07-05
CN105209018A (zh) 2015-12-30
MX367364B (es) 2019-08-16
JP2017019880A (ja) 2017-01-26
EP2943185A1 (en) 2015-11-18
US8999393B1 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
JP2017537168A5 (enExample)
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
ES2623176T3 (es) Composición farmacéutica de memantina
HRP20231478T1 (hr) Csf1r inhibitori za primjenu u liječenju raka
JP2012144577A5 (enExample)
MX2015011896A (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
HRP20192119T1 (hr) Pripravak i metoda za pomoć pri spavanju
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
CN106389381A (zh) 金刚烷胺组合物及其使用方法
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
JP2015038135A5 (enExample)
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
JP2013231087A5 (enExample)
JP2014528431A5 (enExample)
EA031255B1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
RU2014142025A (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
JP2015503583A5 (enExample)
JP2019509345A5 (enExample)
JP2015510928A5 (enExample)
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
HRP20192184T1 (hr) Optimizirana visokodozna tableta mesalazina